ArticleFrontiers in oncology2023

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report.

Junzhu Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.